Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bluejay Diagnostics Inc (BJDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: BJDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.89% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.42M USD | Price to earnings Ratio 0.01 | 1Y Target Price 256 |
Price to earnings Ratio 0.01 | 1Y Target Price 256 | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 1.46 - 37.50 | Updated Date 06/29/2025 |
52 Weeks Range 1.46 - 37.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 277.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -80.05% | Return on Equity (TTM) -200.56% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value -508155 | Price to Sales(TTM) 54.99 |
Enterprise Value -508155 | Price to Sales(TTM) 54.99 | ||
Enterprise Value to Revenue 5.67 | Enterprise Value to EBITDA -0.1 | Shares Outstanding 1494180 | Shares Floating 1125089 |
Shares Outstanding 1494180 | Shares Floating 1125089 | ||
Percent Insiders 0.26 | Percent Institutions 2.48 |
Upturn AI SWOT
Bluejay Diagnostics Inc
Company Overview
History and Background
Bluejay Diagnostics, Inc., founded in 2016, is a medical diagnostic company focused on developing and commercializing point-of-care diagnostic products. Its focus is on developing diagnostic tests that can be used at the point of care to improve patient outcomes.
Core Business Areas
- Point-of-Care Diagnostics: Bluejay focuses on developing and commercializing point-of-care diagnostics, primarily for acute care settings. This is their main business area.
Leadership and Structure
The leadership team includes individuals with experience in diagnostics and medical device development. The organizational structure is typical of a small, publicly traded company, with distinct departments for research and development, operations, and finance.
Top Products and Market Share
Key Offerings
- Symphony System: Bluejay's lead product is the Symphony System, a platform intended for rapid, point-of-care testing for acute infections like sepsis. The market share is currently minimal as it is still in development and commercialization phase. Competitors include companies offering rapid diagnostic platforms like Roche, Abbott, and BioMerieux.
Market Dynamics
Industry Overview
The point-of-care diagnostics market is growing, driven by the need for rapid and accurate diagnostic testing in various healthcare settings. Key trends include miniaturization, connectivity, and integration with electronic health records.
Positioning
Bluejay is positioned as an emerging player in the point-of-care diagnostics market, focusing on the acute care setting. The competitive advantage is its platform approach, offering the potential to develop multiple tests on a single system.
Total Addressable Market (TAM)
The global point-of-care diagnostics market is expected to reach billions of USD. Bluejay aims to capture a portion of this market through its Symphony system, but the TAM is large and highly competitive.
Upturn SWOT Analysis
Strengths
- Novel diagnostic platform
- Focus on unmet needs in acute care
- Experienced management team
Weaknesses
- Limited commercial traction
- Reliance on key personnel
- Cash burn rate
- Dependence on regulatory approvals
Opportunities
- Strategic partnerships
- Expansion into new diagnostic areas
- Increasing demand for point-of-care testing
Threats
- Competition from established players
- Technological obsolescence
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Abbott (ABT)
- BioMerieux (BIM.PA)
Competitive Landscape
Bluejay faces significant competition from larger, established companies. Its advantage is its novel technology, but it needs to prove its clinical utility and secure market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal, reflecting the company's focus on product development.
Future Projections: Future growth depends on the successful commercialization of the Symphony system and securing regulatory approvals. Projections are not readily available.
Recent Initiatives: Recent initiatives include clinical trials for the Symphony system and securing partnerships.
Summary
Bluejay Diagnostics is a small medical device company focused on developing point-of-care diagnostics. Its main product is the Symphony system. The company is operating at a loss. It faces competition from larger companies and risks due to clinical trials and regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Market Analysis
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be limited or delayed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bluejay Diagnostics Inc
Exchange NASDAQ | Headquaters Acton, MA, United States | ||
IPO Launch date 2021-11-10 | Principal Financial, Accounting & Executive Officer, President, CEO and Director Mr. Indranil Dey | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7 | Website https://bluejaydx.com |
Full time employees 7 | Website https://bluejaydx.com | ||
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.